IL1B and hydrops fetalis: This aligns with prior evidence from the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, which demonstrated that targeted IL-1β inhibition with canakinumab reduced HF hospitalizations, highlighting the role of inflammatory pathways in HF pathophysiology [180].